RDHL Redhill Biopharma Ltd.

10.36
+0  (1%)
Previous Close 10.30
Open 10.25
Price To book 2.71
Market Cap 176.72M
Shares 17,058,000
Volume 39,628
Short Ratio 2.67
Av. Daily Volume 69,490

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b to be initiated 1H 2017.
YELIVA
Prevention of mucositis in cancer patients undergoing therapeutic radiotherapy
Phase 1/2 trial initiation announced September 8, 2016. Announced that dosing has commenced - December 19, 2016.
YELIVA
Refractory or relapsed multiple myeloma - cancer
Planned resubmission of NDA due 1H 2017.
RIZAPORT (RHB-103)
Migraine
Phase 3 DSMB safety analysis released December 13, 2016 - trial to continue as planned. Interim efficacy analysis due mid-2017.
RHB-104 MAP US
Crohn’s disease
Phase 3 final data released March 2016. Additional Phase 3 trial planned to be 2Q 2017.
RHB-105
H. pylori
Phase 3 enrollment of final patient announced February 13, 2017 with top-line data due 2Q 2017.
BEKINDA -GUARD
Gastroenteritis
Phase 2a data released December 12, 2016.
RHB-104 CEASE-MS
Multiple sclerosis
Phase 2 top-line data due mid 2017.
BEKINDA
IBS-D
Phase 2 initiated October 2016.
YELIVA
Hepatocellular carcinoma (HCC) - cancer
Phase 2 to be initiated 2H 2016
YELIVA
Mucositis in cancer patients
Phase 1/2 trial amended to include Kaposi sarcoma patients. Trial due to resume in late 2016.
YELIVA
Refractory/relapsed diffuse large B-cell lymphoma (DLBCL)

Latest News

  1. RedHill Biopharma to Present at the 2017 MAP Conference
  2. RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn's Disease
  3. RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn's Disease
  4. RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn’s Disease
  5. RedHill Biopharma Ltd. :RDHL-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  6. RedHill Biopharma to Present at the BIO-Europe Spring 2017 Conference
  7. RedHill Biopharma’s Co-Promotion Partner Concordia Announces U.S. District Court Grants Treble Damages Relating to Donnatal®
  8. REDHILL BIOPHARMA LTD. Financials
  9. RedHill Biopharma Announces Availability of Its Annual Report on Form 20-F Through Its Website
  10. RedHill Biopharma Reports 2016 Fourth Quarter and Full-Year Financial Results
  11. RedHill Biopharma Reports 2016 Fourth Quarter and Full-Year Financial Results
  12. RedHill Biopharma Completes Treatment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis
  13. RedHill Biopharma Completes Treatment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis
  14. RedHill Biopharma to Host Fourth Quarter and Full-Year 2016 Financial Results Conference Call on February 23, 2017
  15. RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis
  16. RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis
  17. The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma
  18. 4 Drug Stocks that are Broker Favorites
  19. RedHill Biopharma to Present at the BIO CEO & Investor Conference
  20. The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma